A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

Overview of attention for article published in European Journal of Nuclear Medicine and Molecular Imaging, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#22 of 3,472)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 11 news stories from 11 outlets.

95% of patients (36 of 38) treated withAriceum's radiopharmaceutical satoreotide achieved disease control in Phase I/II trial…

Ariceum Therapeutics announce the publication of positive results from a Phase I/II trial of its radiopharmaceutical 177Lu-satore…

BERLIN, Sept. 28, 2023 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 7 additional news stories.